Not many patients are interested in the procedure world wide as we can see from sales, if they were they would fly anywhere to get treatment for extending their life. The company should be happy to release last quarters operations on patients. Then we can objectively assess if we should hold the stock any more.
Ann: First Patient in Australia Randomised in TRIPP-FFX Trial, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.010(1.06%) |
Mkt cap ! $13.51M | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | $1.02 | 94.0¢ | $110.7K | 114.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15628 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 1909 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |